Mario Perro
University College London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mario Perro.
The Lancet | 2010
Erik-Oliver Glocker; Natalie Frede; Mario Perro; Nj Sebire; Mamoun Elawad; Neil Shah; Bodo Grimbacher
Department of Immunology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK (E-O Glocker MD, M Perro MSc, Prof B Grimbacher MD); Department of Haematology, University Hospital Freiburg, Freiburg, Germany (N Frede); Department of Paediatric Laboratory Medicine (Prof N Sebire MD) and Department of Paediatric Gastroenterology (M Elawad MD, N Shah MD), Great Ormond Street Hospital, University College London, London, UK
The Journal of Allergy and Clinical Immunology | 2010
Cristina Woellner; E. Michael Gertz; Alejandro A. Schäffer; Macarena Lagos; Mario Perro; Erik Glocker; Maria Cristina Pietrogrande; Fausto Cossu; José Luis Franco; Nuria Matamoros; Barbara Pietrucha; Edyta Heropolitańska-Pliszka; Mehdi Yeganeh; Mostafa Moin; Teresa Espanol; Stephan Ehl; Andrew R. Gennery; Mario Abinun; Anna Bręborowicz; Tim Niehues; Sara Sebnem Kilic; Anne K. Junker; Stuart E. Turvey; Alessandro Plebani; Berta Sanchez; Ben Zion Garty; Claudio Pignata; Caterina Cancrini; Jiri Litzman; Ozden Sanal
BACKGROUND The hyper-IgE syndrome (HIES) is a primary immunodeficiency characterized by infections of the lung and skin, elevated serum IgE, and involvement of the soft and bony tissues. Recently, HIES has been associated with heterozygous dominant-negative mutations in the signal transducer and activator of transcription 3 (STAT3) and severe reductions of T(H)17 cells. OBJECTIVE To determine whether there is a correlation between the genotype and the phenotype of patients with HIES and to establish diagnostic criteria to distinguish between STAT3 mutated and STAT3 wild-type patients. METHODS We collected clinical data, determined T(H)17 cell numbers, and sequenced STAT3 in 100 patients with a strong clinical suspicion of HIES and serum IgE >1000 IU/mL. We explored diagnostic criteria by using a machine-learning approach to identify which features best predict a STAT3 mutation. RESULTS In 64 patients, we identified 31 different STAT3 mutations, 18 of which were novel. These included mutations at splice sites and outside the previously implicated DNA-binding and Src homology 2 domains. A combination of 5 clinical features predicted STAT3 mutations with 85% accuracy. T(H)17 cells were profoundly reduced in patients harboring STAT3 mutations, whereas 10 of 13 patients without mutations had low (<1%) T(H)17 cells but were distinct by markedly reduced IFN-gamma-producing CD4(+)T cells. CONCLUSION We propose the following diagnostic guidelines for STAT3-deficient HIES. Possible: IgE >1000IU/mL plus a weighted score of clinical features >30 based on recurrent pneumonia, newborn rash, pathologic bone fractures, characteristic face, and high palate. Probable: These characteristics plus lack of T(H)17 cells or a family history for definitive HIES. Definitive: These characteristics plus a dominant-negative heterozygous mutation in STAT3.
Gene Therapy | 2010
Mario Perro; Julia Yuen-Shan Tsang; Shao-An Xue; D. Escors; Michela Cesco-Gaspere; C Pospori; Liquan Gao; Daniel P. Hart; Mary Collins; Hans J. Stauss; Emma Morris
T-cell receptor (TCR) gene transfer is an attractive strategy to generate antigen-specific T-cells for adoptive immunotherapy of cancer and chronic viral infection. However, current TCR gene transfer protocols trigger T-cell differentiation into terminally differentiated effector cells, which likely have reduced ability to mediate disease protection in vivo. We have developed a lentiviral gene transfer strategy to generate TCR-transduced human T-cells without promoting T-cell differentiation. We found that a combination of interleukin-15 (IL15) and IL21 facilitated lentiviral TCR gene transfer into non-proliferating T-cells. The transduced T-cells showed redirection of antigen specificity and produced IL2, IFNγ and TNFα in a peptide-dependent manner. A significantly higher proportion of the IL15/IL21-stimulated T-cells were multi-functional and able to simultaneously produce all three cytokines (P<0.01), compared with TCR-transduced T-cells generated by conventional anti-CD3 plus IL2 stimulation, which primarily secreted only one cytokine. Similarly, IL15/IL21 maintained high levels of CD62L and CD28 expression in transduced T-cells, whereas anti-CD3 plus IL2 accelerated the loss of CD62L/CD28 expression. The data demonstrate that the combination of lentiviral TCR gene transfer together with IL15/IL21 stimulation can efficiently redirect the antigen specificity of resting primary human T-cells and generate multi-functional T-cells.
Blood | 2011
Constandina Pospori; Shao-An Xue; A Holler; C Voisine; Mario Perro; J King; Farnaz Fallah-Arani; Barry Flutter; Ronjon Chakraverty; Hans J. Stauss; Emma Morris
Recently, vaccines against the Wilms Tumor antigen 1 (WT1) have been tested in cancer patients. However, it is currently not known whether physiologic levels of WT1 expression in stem and progenitor cells of normal tissue result in the deletion or tolerance induction of WT1-specific T cells. Here, we used an human leukocyte antigen-transgenic murine model to study the fate of human leukocyte antigen class-I restricted, WT1-specific T cells in the thymus and in the periphery. Thymocytes expressing a WT1-specific T-cell receptor derived from high avidity human CD8 T cells were positively selected into the single-positive CD8 population. In the periphery, T cells specific for the WT1 antigen differentiated into CD44-high memory phenotype cells, whereas T cells specific for a non-self-viral antigen retained a CD44(low) naive phenotype. Only the WT1-specific T cells, but not the virus-specific T cells, displayed rapid antigen-specific effector function without prior vaccination. Despite long-term persistence of WT1-specific memory T cells, the animals did not develop autoimmunity, and the function of hematopoietic stem and progenitor cells was unimpaired. This is the first demonstration that specificity for a tumor-associated self-antigen may drive differentiation of functionally competent memory T cells.
Journal of Translational Medicine | 2010
Erik-Oliver Glocker; Daniel Kotlarz; Kaan Boztug; E M Gertz; Alejandro A. Schäffer; Fatih Noyan; Mario Perro; Jana Diestelhorst; Anna Allroth; Dhaarini Murugan; Nadine Hätscher; Dietmar Pfeifer; Karl-Walter Sykora; Martin G. Sauer; Hans Kreipe; Martin Lacher; Rainer Nustede; Cristina Woellner; Ulrich Baumann; U Salzer; Sibylle Koletzko; Neil P. Shah; Anthony W. Segal; A Sauerbrey; S Buderus; Scott B. Snapper; Bodo Grimbacher; Christoph Klein
Methods We performed genetic linkage analysis and candidate gene sequencing in two unrelated consanguineous families with children affected by early-onset IBD. We screened six additional patients for mutations in two candidate genes and carried out functional assays in patients’ peripheral blood mononuclear cells. We treated one patient with an allogeneic hematopoietic stem cell transplant (HSCT).
The New England Journal of Medicine | 2009
Erik-Oliver Glocker; Daniel Kotlarz; Kaan Boztug; E. Michael Gertz; Alejandro A. Schäffer; Fatih Noyan; Mario Perro; Jana Diestelhorst; Anna Allroth; Dhaarini Murugan; Nadine Hätscher; Dietmar Pfeifer; Karl-Walter Sykora; Martin G. Sauer; Hans Kreipe; Martin Lacher; Rainer Nustede; Cristina Woellner; Ulrich Baumann; Ulrich Salzer; Sibylle Koletzko; Neil Shah; Anthony W. Segal; Axel Sauerbrey; Stephan Buderus; Scott B. Snapper; Bodo Grimbacher; Christoph Klein
Molecular Therapy | 2007
Hans J. Stauss; Michela Cesco-Gaspere; Sharyn Thomas; Daniel P. Hart; Shao-An Xue; A Holler; Graham P. Wright; Mario Perro; Ann-Margaret Little; C Pospori; Judy King; Emma Morris
Blood Cells Molecules and Diseases | 2008
Hans J. Stauss; Sharyn Thomas; Michela Cesco-Gaspere; Daniel P. Hart; Shao-An Xue; A Holler; Judy King; Graham P. Wright; Mario Perro; C Pospori; Emma Morris
The Lancet | 2010
Erik-Oliver Glocker; Natalie Frede; Mario Perro; Nj Sebire; Mamoun Elawad; Neil P. Shah; Bodo Grimbacher
In: HUMAN GENE THERAPY. (pp. 512 - 512). MARY ANN LIEBERT INC (2010) | 2010
Mario Perro; Julia Yuen-Shan Tsang; Sa Xue; D. Escors; Michela Cesco-Gaspere; D Pospori; Liquan Gao; Daniel P. Hart; Mary Collins; Hans J. Stauss; Emma Morris